EA202091598A3 - Процесс контроля уровня содержания гликанов в составе - Google Patents

Процесс контроля уровня содержания гликанов в составе

Info

Publication number
EA202091598A3
EA202091598A3 EA202091598A EA202091598A EA202091598A3 EA 202091598 A3 EA202091598 A3 EA 202091598A3 EA 202091598 A EA202091598 A EA 202091598A EA 202091598 A EA202091598 A EA 202091598A EA 202091598 A3 EA202091598 A3 EA 202091598A3
Authority
EA
Eurasian Patent Office
Prior art keywords
content
glycans
composition
control
controlling
Prior art date
Application number
EA202091598A
Other languages
English (en)
Other versions
EA202091598A2 (ru
Inventor
Дэниел Р. Лейске
Майкл Т. Тренталанж
Original Assignee
Эмджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55024253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202091598(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эмджен Инк. filed Critical Эмджен Инк.
Publication of EA202091598A2 publication Critical patent/EA202091598A2/ru
Publication of EA202091598A3 publication Critical patent/EA202091598A3/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2523/00—Culture process characterised by temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

В настоящем изобретении предложен способ управления содержанием фукозилированных гликанов в рекомбинантном белке.
EA202091598A 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе EA202091598A3 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462085759P 2014-12-01 2014-12-01

Publications (2)

Publication Number Publication Date
EA202091598A2 EA202091598A2 (ru) 2020-10-30
EA202091598A3 true EA202091598A3 (ru) 2021-01-29

Family

ID=55024253

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201791223A EA036178B1 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе гликопротеинов
EA202091598A EA202091598A3 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201791223A EA036178B1 (ru) 2014-12-01 2015-12-01 Процесс контроля уровня содержания гликанов в составе гликопротеинов

Country Status (23)

Country Link
US (5) US10167492B2 (ru)
EP (2) EP3227454B1 (ru)
JP (3) JP6698681B2 (ru)
KR (1) KR102623965B1 (ru)
CN (1) CN107109455B (ru)
AU (3) AU2015355087B2 (ru)
BR (1) BR112017011652A2 (ru)
CA (1) CA2969225C (ru)
CL (1) CL2017001369A1 (ru)
CY (1) CY1123247T1 (ru)
DK (1) DK3227454T3 (ru)
EA (2) EA036178B1 (ru)
ES (1) ES2784503T3 (ru)
HU (1) HUE049201T2 (ru)
IL (2) IL276165B (ru)
LT (1) LT3227454T (ru)
MX (1) MX2017006997A (ru)
PL (1) PL3227454T3 (ru)
PT (1) PT3227454T (ru)
SG (2) SG10202002458PA (ru)
SI (1) SI3227454T1 (ru)
WO (1) WO2016089919A1 (ru)
ZA (2) ZA201703729B (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein
MA47775A (fr) * 2017-03-14 2020-01-22 Amgen Inc Contrôle des glycoformes afucosylées totales d'anticorps produits en culture cellulaire
EP3601586A1 (en) * 2017-03-31 2020-02-05 Boehringer Ingelheim International GmbH Perfusion medium
WO2019105444A1 (zh) * 2017-11-30 2019-06-06 正大天晴药业集团南京顺欣制药有限公司 蛋白质的生产方法
MA52186A (fr) * 2018-03-26 2021-02-17 Amgen Inc Glycoformes afucosylées totales d'anticorps produits en culture cellulaire
JP2021524745A (ja) * 2018-05-24 2021-09-16 アレス トレーディング ソシエテ アノニム 糖タンパク質組成物の非フコシル化レベルを制御する方法
WO2019236739A1 (en) 2018-06-05 2019-12-12 Amgen Inc. Modulating antibody dependent cellular phagocytosis
WO2020055900A1 (en) 2018-09-11 2020-03-19 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
HUP1800376A2 (hu) 2018-11-07 2020-05-28 Richter Gedeon Nyrt Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
US20220081479A1 (en) * 2018-12-31 2022-03-17 Momenta Pharmaceuticals, Inc. Methods of producing ustekinumab
EP3917951A1 (en) * 2019-01-30 2021-12-08 Amgen, Inc Aflibercept attributes and methods of characterizing and modifying thereof
JP2023530208A (ja) 2019-05-06 2023-07-14 アムジェン インコーポレイテッド 抗体エフェクター機能の調節
JP2020188737A (ja) * 2019-05-23 2020-11-26 東ソー株式会社 抗体依存性細胞傷害活性が向上した抗体の製造方法
BR112022005583A2 (pt) 2019-09-26 2022-09-20 Amgen Inc Métodos para a produção de composições de anticorpos
WO2022026451A1 (en) * 2020-07-30 2022-02-03 Amgen Inc. Cell culture media and methods of making and using the same
WO2022036275A2 (en) * 2020-08-14 2022-02-17 Bristol-Myers Squibb Company Manufacturing process for protein
CA3197930A1 (en) 2020-10-15 2022-04-21 Amgen Inc. Relative unpaired glycans in antibody production methods
AU2022289365A1 (en) 2021-06-07 2023-12-14 Amgen Inc. Using fucosidase to control afucosylation level of glycosylated proteins
WO2023161885A1 (en) * 2022-02-25 2023-08-31 Kashiv Biosciences, Llc A process for improving polypeptide expression in mammalian cell culture

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
AU588819B2 (en) 1984-10-29 1989-09-28 Immunex Corporation Cloning of human granulocyte-macrophage colony stimulating factor gene
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US6048728A (en) 1988-09-23 2000-04-11 Chiron Corporation Cell culture medium for enhanced cell growth, culture longevity, and product expression
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US6204363B1 (en) 1989-10-16 2001-03-20 Amgen Inc. Stem cell factor
US5272064A (en) 1989-12-19 1993-12-21 Amgen Inc. DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof
US5149792A (en) 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5096816A (en) 1990-06-05 1992-03-17 Cetus Corporation In vitro management of ammonia's effect on glycosylation of cell products through pH control
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
US6284471B1 (en) * 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5981713A (en) 1994-10-13 1999-11-09 Applied Research Systems Ars Holding N.V. Antibodies to intereleukin-1 antagonists
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
ES2253753T3 (es) 1995-06-29 2006-06-01 Immunex Corporation Citocina que induce apoptosis.
US6613544B1 (en) 1995-12-22 2003-09-02 Amgen Inc. Osteoprotegerin
US6096728A (en) 1996-02-09 2000-08-01 Amgen Inc. Composition and method for treating inflammatory diseases
US6271349B1 (en) 1996-12-23 2001-08-07 Immunex Corporation Receptor activator of NF-κB
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6337072B1 (en) 1998-04-03 2002-01-08 Hyseq, Inc. Interleukin-1 receptor antagonist and recombinant production thereof
US6528286B1 (en) 1998-05-29 2003-03-04 Genentech, Inc. Mammalian cell culture process for producing glycoproteins
JP2001120262A (ja) * 1999-10-26 2001-05-08 Welfide Corp 生理活性物質の産生増強方法
AU1920301A (en) 1999-11-17 2001-05-30 Immunex Corporation Receptor activator of nf-kappa b
US6544424B1 (en) 1999-12-03 2003-04-08 Refined Technology Company Fluid filtration system
EE05458B1 (et) 2000-05-26 2011-08-15 Bristol-Myers Squibb Company CTL4 lahustuvad mutantsed molekulid ja nende kasutamine
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
DE10312765A1 (de) 2003-03-21 2004-09-30 Bayer Technology Services Gmbh Vorrichtung und Verfahren zur Sterilisation flüssiger Medien mittels UV-Bestrahlung und Kurzzeiterhitzung
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
US8053238B2 (en) 2005-10-31 2011-11-08 Unhwa Corporation Isolated population of plant single cells and method of preparing the same
US20070231895A1 (en) 2005-11-02 2007-10-04 Lee Gene W Methods for adapting mammalian cells
US7972810B2 (en) 2005-12-08 2011-07-05 Amgen Inc. Production of glycoproteins using manganese
WO2007081031A1 (ja) * 2006-01-16 2007-07-19 Hokkaido University 糖転移酵素阻害剤
AU2007272957B2 (en) 2006-07-13 2014-05-01 Wyeth Llc Production of glycoproteins
US20100166741A1 (en) * 2006-07-13 2010-07-01 Genentech , Inc. Altered br-3 binding polypeptides
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
EP2064315B1 (en) 2006-11-03 2015-05-13 Wyeth LLC Glycolysis-inhibiting substances in cell culture
EP2924113B1 (en) 2007-03-02 2019-04-10 Wyeth LLC Use of copper and glutamate in cell culture for production of polypeptides
JP2010523119A (ja) * 2007-03-30 2010-07-15 セントコア・オーソ・バイオテツク・インコーポレーテツド 蛍光性プロテインａもしくはｇを用いた哺乳動物細胞の高発現クローン
US20100113294A1 (en) 2007-04-16 2010-05-06 Momenta Pharmaceuticals, Inc. Defined glycoprotein products and related methods
US20100221823A1 (en) 2007-06-11 2010-09-02 Amgen Inc. Method for culturing mammalian cells to improve recombinant protein production
MX2009013762A (es) 2007-06-15 2010-03-01 Amgen Inc Metodos para tratar medios de cultivo de celulas para uso en biorreactor.
CA2763164A1 (en) 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
RU2013122843A (ru) 2010-10-20 2014-11-27 Морфотек, Инк. Гликоформы антитела против фолатного рецептора альфа
KR20130129438A (ko) 2011-02-23 2013-11-28 암젠 인크 Uvc 노출을 위한 세포 배양 배지 및 이와 관련된 방법
US9574003B2 (en) * 2011-03-06 2017-02-21 Merck Serono S.A. Low fucose cell lines and uses thereof
WO2012145682A1 (en) 2011-04-21 2012-10-26 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
WO2013006479A2 (en) 2011-07-01 2013-01-10 Amgen Inc. Mammalian cell culture
AR087433A1 (es) * 2011-08-08 2014-03-26 Merck Sharp & Dohme Analogos de insulina n-glicosilados
BR112014008303A2 (pt) 2011-09-16 2017-04-11 Amgen Inc alimentação contínua controlada pré-programada sem feedback de culturas celulares
EA034347B1 (ru) 2011-10-26 2020-01-30 Амген Инк. Способ инактивации вирусов при получении антител
CN104487570A (zh) * 2012-01-20 2015-04-01 新加坡科技研究局 Cho-gmt重组蛋白的表达
EP2809773B1 (en) 2012-01-30 2020-09-02 Dr. Reddy's Laboratories Limited Process of modulating man5 and/or afucosylation content of glycoprotein composition
WO2013114164A1 (en) * 2012-01-30 2013-08-08 Dr. Reddy's Laboratories Limited Method for obtaining glycoprotein composition with increased afucosylation content
WO2013138159A1 (en) 2012-03-15 2013-09-19 Amgen Inc. Methods of determining exposure to uv light
US10481164B2 (en) 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
EP2905290B1 (en) * 2012-10-05 2019-12-04 Kyowa Kirin Co., Ltd. Heterodimeric protein composition
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US9677105B2 (en) 2013-03-14 2017-06-13 Momenta Pharmaceuticals, Inc. Methods of cell culture
EP3024922A4 (en) 2013-07-23 2017-03-29 Biocon Limited Methods for controlling fucosylation levels in proteins
SI3110961T1 (sl) 2014-02-27 2020-03-31 F. Hoffmann-La Roche Ag Modulacija rasti celic in glikozilacije pri rekombinantni proizvodnji glikoproteina
WO2016068799A1 (en) * 2014-10-27 2016-05-06 Agency For Science, Technology And Research Methods of recombinant protein expression in a cell comprising reduced udp-galactose transporter activity
EP3227454B1 (en) 2014-12-01 2020-01-29 Amgen Inc. Process for manipulating the level of glycan content of a glycoprotein

Also Published As

Publication number Publication date
EA202091598A2 (ru) 2020-10-30
EA201791223A1 (ru) 2017-10-31
DK3227454T3 (da) 2020-04-14
CN107109455B (zh) 2022-02-18
IL276165B (en) 2022-11-01
ES2784503T3 (es) 2020-09-28
US20230159974A1 (en) 2023-05-25
PT3227454T (pt) 2020-04-06
SG10202002458PA (en) 2020-04-29
JP2020124216A (ja) 2020-08-20
US20190085370A1 (en) 2019-03-21
US20210017565A1 (en) 2021-01-21
ZA201703729B (en) 2021-03-31
EP3680344A1 (en) 2020-07-15
AU2015355087A1 (en) 2017-06-29
CN107109455A (zh) 2017-08-29
BR112017011652A2 (pt) 2018-06-26
US20170362625A1 (en) 2017-12-21
PL3227454T3 (pl) 2020-07-27
MX2017006997A (es) 2017-10-16
IL252569A0 (en) 2017-07-31
HUE049201T2 (hu) 2020-09-28
AU2022200586A1 (en) 2022-02-24
AU2020202302A1 (en) 2020-04-23
IL252569B (en) 2020-08-31
EP3227454A1 (en) 2017-10-11
CY1123247T1 (el) 2021-10-29
EP3227454B1 (en) 2020-01-29
EA036178B1 (ru) 2020-10-09
ZA202006002B (en) 2022-03-30
JP2017538446A (ja) 2017-12-28
US10822630B2 (en) 2020-11-03
IL276165A (en) 2020-09-30
JP2022101669A (ja) 2022-07-06
SG11201704351WA (en) 2017-06-29
US10167492B2 (en) 2019-01-01
WO2016089919A1 (en) 2016-06-09
CA2969225A1 (en) 2016-06-09
SI3227454T1 (sl) 2020-06-30
KR20170083636A (ko) 2017-07-18
CA2969225C (en) 2023-08-22
LT3227454T (lt) 2020-07-27
US20200172947A1 (en) 2020-06-04
CL2017001369A1 (es) 2018-02-23
JP6698681B2 (ja) 2020-05-27
JP7066775B2 (ja) 2022-05-13
KR102623965B1 (ko) 2024-01-11
AU2015355087B2 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
EA202091598A2 (ru) Процесс контроля уровня содержания гликанов в составе
HK1244185A1 (zh) 用於生成卵清蛋白的方法和組合物
GB2568806B (en) I/O virtualization for commissioning
EP3245722A4 (en) Switching regulator and control method thereof
EP3135826A4 (en) Construction machine and method for controlling construction machine
EP3236335A4 (en) Electronic instrument, method of controlling electronic instrument, and control program for same
IL263342A (en) A method for stabilizing proteins
EP3149176A4 (en) Methods for altering polypeptide expression
HUP1500363A2 (en) Method for increasing the galactose content of recombinant proteins
IL254765A0 (en) A method for the monomerization of recombinant antibody molecules
EP3205083A4 (en) Control apparatus, method of controlling the same and program
EP3056379C0 (de) Verfahren zur steuerung oder regelung einer betriebsvorrichtung
EP3256589A4 (en) Compositions and methods for controlling leptinotarsa
EP3312278A4 (en) Protein expression method
EP3105481A4 (en) In-line control valve
EP3572507A4 (en) EXPRESSION METHOD FOR RECOMBINANT HAEMOCOAGULASE ACUTUS PROTEIN
IL255094A0 (en) A method for increasing the percentage of multimeric strains for a monomeric dsfv-fab antibody
MY165602A (en) Engine controller and engine control method
GB201502818D0 (en) Metasurface for control of light propogation
GB201515284D0 (en) Well control method
EP3139299A4 (en) Control program delivery system and method therefor
EP3495491A4 (en) PROCESS FOR PRODUCING RECOMBINANT PROTEIN
DK3127917T3 (da) Fremgangsmåde til fremstilling af antistof gennem regulering af sukkerindhold i antistof
HUE058103T2 (hu) Saját közegszabályozású szabályozó szelep
ZA201704299B (en) Modified cry1ca toxins useful for control of insect pests